This article first appeared on GuruFocus .
-
Net Sales:$17.8 million for Q2 2026, an 11% increase year-over-year.
-
Gross Profit:$3.2 million in Q2 2026, a 30% improvement from the prior year period.
-
Gross Margin:Expanded to 18% in Q2 2026, up from 16% in Q2 2025 and 17% in Q1 2026.
-
Net Loss:$1.2 million for Q2 2026, improved from a net loss of $1.5 million in Q2 2025.
-
Adjusted EBITDA:Negative $200,000 for Q2 2026, consistent with the prior year period.
-
Cash Flow from Operations:Generated approximately $2.1 million in Q2 2026.
-
Cash Position:$24.8 million in cash equivalents and investments at quarter-end, up from $23.9 million at the end of Q1 2026.
-
Full-Year 2026 Guidance:Reiterated net sales between $70 million and $75 million, gross margin between 18% and 22%, adjusted EBITDA between $1 million and $2 million, and positive operating cash flow.
Release Date: August 13, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Rockwell Medical Inc ( NASDAQ:RMTI ) reported an 11% year-over-year increase in net sales for Q2 2026, driven by new customer growth and increased purchase activity.
-
Gross margin expanded to 18% in Q2 2026, up from 16% in the prior year period, reflecting improved operational efficiency and higher volumes.
-
The company generated approximately $2.1 million in positive operating cash flow during the quarter, ending with a strong cash balance of $24.8 million.
-
Rockwell Medical Inc ( NASDAQ:RMTI ) successfully signed a new agreement with Heritage Dialysis and renewed its long-standing relationship with Aqua Dialysis, strengthening its recurring revenue base.
-
The company is making significant progress in the Western United States, a key growth area, with new customers transitioning business and contributing to higher-margin liquid product sales.
-
Management reiterated its full-year 2026 guidance, expecting net sales between $70 million and $75 million, gross margin between 18% and 22%, and positive operating cash flow.
Negative Points
-
Rockwell Medical Inc ( NASDAQ:RMTI ) still reported a net loss of $1.2 million for Q2 2026, although this was an improvement from the $1.5 million loss in the prior year period.
-
Adjusted EBITDA remained negative at -$200,000 for the second quarter, consistent with the prior year period.
-
The company's six-month net sales were flat year-over-year, with growth only visible when excluding the impact of higher purchasing volumes from DaVita in the prior year.
-
The company incurred expenses related to the evaluation and development of a new medical device opportunity, which represents a new area of investment risk.
-
Management acknowledged a 'meaningful disconnect' between the company's current market valuation and its operational progress, indicating the stock price may not reflect the business's performance.
-
The company had to complete a reverse stock split to regain compliance with NASDAQ's minimum bid price requirement, which can be viewed negatively by some investors.
Q & A Highlights
Q: Can you provide more details on the new medical device opportunity mentioned earlier? How should we think about it compared to your current product portfolio? Will it be bundled with existing products or used independently? A: Mark Strobeck (President and CEO): This opportunity was selected because it folds directly into our existing product portfolio and targets a large market. The data supports that if we develop, register, and distribute this product, we could potentially be the only other supplier of this type of product in the United States. Importantly, this development will be entirely funded by our balance sheet within our existing operating plan, so we do not need to raise additional capital to support it.
Q: How is the expansion into the West Coast market progressing, and what is the strategy for building operations there? A: Mark Strobeck (President and CEO): The West Coast is a strategic objective as there is primarily only one supplier of concentrates in that region, creating a significant market opportunity. We have onboarded a customer base in the West and are now supplying them consistently. This presence allows our sales force to engage other customers, informing them that Rockwell is now a viable alternative with a full suite of manufactured and distributed concentrates. We are seeing positive interactions and expect this part of the business to continue growing.
Q: What do the renewal structures for your customer contracts look like? Are they multi-year agreements, and when are renewal options triggered? A: Mark Strobeck (President and CEO): Our standard supply agreements are approximately three years in length with set pricing and standard price escalators based on products and volumes. We typically begin discussions with partners about six months before the agreement ends. Given our performance and their needs, these discussions have successfully translated into extensions for longer periods.
Q: Beyond manufacturing costs and volume drivers, is there a product mix component to the West Coast growth and your path towards the high end of the 18% to 22% margin guide? What is the plan to keep growing that Western business? A: Jesse Neri (SVP Finance) and Mark Strobeck (President and CEO): The Western product mix is more skewed towards our liquid products, where we are the leading manufacturer, which generally carries a higher margin profile. To continue growing the customer base, we are educating dialysis centers in the West that Rockwell is now present and manufacturing products. We are aggressively meeting with clinics of all sizes to let them know there is an alternative to the single provider they have been locked into. The success of our current supply is also creating a positive ripple effect in the marketplace.
Q: For the incremental volume growth, does it carry a margin similar to the corporate average, or is there dilution from freight and onboarding costs as this business matures? A: Mark Strobeck (President and CEO): The incremental growth seen over the quarter is consistently higher than the corporate average margin.
Q: Can you elaborate on the financial results for the second quarter, specifically regarding net sales and the impact of the DaVita relationship? A: Jesse Neri (SVP Finance): Net sales for Q2 2026 were $17.8 million, an 11% increase year-over-year, driven by new customers in the Western U.S., increased purchasing from existing customers, and annual pricing actions. For the six-month period, sales were $35.1 million, in line with the prior year. However, the first half of 2025 included higher purchasing volumes from DaVita. Excluding DaVita, first half 2026 sales grew by more than 10% over the prior year, and we delivered sequential growth with Q2 sales exceeding Q1.
Q: What were the key drivers of the gross margin expansion in the second quarter? A: Jesse Neri (SVP Finance): Gross margin expanded to 18% in Q2 2026, up from 16% in the prior year period and 17% in Q1 2026. This improvement reflects the benefit of lower manufacturing costs and operational efficiency initiatives, including our most recent automation investments. As production volumes increase and asset utilization improves, we believe there remains additional opportunity for margin expansion.
Q: Can you provide an update on the company's cash flow and liquidity position? A: Jesse Neri (SVP Finance): The company generated approximately $2.1 million of cash from operations during the second quarter. This contributed to a quarter-end balance of $24.8 million in cash and investments, which increased from $23.9 million at the end of Q1 and remained consistent with year-end 2025, despite continued investments and final payments associated with the Avoca acquisition. This strong cash position provides flexibility to support growth initiatives and pursue strategic opportunities.
Q: What is the company's full-year 2026 guidance? A: Jesse Neri (SVP Finance): Based on performance through the first half of the year and current business trends, we are reiterating our full-year 2026 guidance. We expect net sales between $70 million and $75 million, gross margin between 18% and 22%, adjusted EBITDA between $1 million and $2 million, and positive operating cash flow.
Q: Can you address the recently completed reverse stock split and its context compared to prior periods? A: Mark Strobeck (President and CEO): The reverse stock split was undertaken to regain compliance with NASDAQ's minimum bid price requirement and to increase interest from institutional investors. Unlike prior periods, this was not driven by a need to raise capital, deterioration in operating performance, or liquidity concerns. At the time of the split, Rockwell had demonstrated continued revenue growth, improving profitability, positive operating cash flow, and a strengthened balance sheet. Since completing the split, we have regained compliance with NASDAQ's listing requirements, and the matter is closed.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
